CAMP4 to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 16:05:00 -0400

WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the Company will participate in the following upcoming investor conferences:

Wells Fargo 21st Annual Healthcare Conference

Format:

CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the Company will participate in the following upcoming investor conferences:

Wells Fargo 21st Annual Healthcare Conference

Format:

click here.

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

Thu, 13 Aug 2026 16:05:00 -0400

Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth quarter of this year.

Received $50.1 million from fully subscribed second closing of private placement initially announced September 2025. Cash runway extended through the end of 2028.

WATERTOWN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

Thu, 13 Aug 2026 16:05:00 -0400

Received $50.1 million from fully subscribed second closing of private placement initially announced September 2025. Cash runway extended through the end of 2028.

Form 4 Camp4 Therapeutics Corp For: Aug 03 Filed by: 5AM Ventures VII, L.P.

Wed, 05 Aug 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20260805/26876181.html

Form 4 Camp4 Therapeutics Corp For: Aug 03 Filed by: Schwab Andrew J.

Wed, 05 Aug 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260805/26876121.html

Form 4 Camp4 Therapeutics Corp For: Aug 03 Filed by: Young Richard A

Wed, 05 Aug 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260805/26875815.html

Form 4 Camp4 Therapeutics Corp For: Aug 03 Filed by: Maricich Yuri

Wed, 05 Aug 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20260805/26875801.html

Form 4 Camp4 Therapeutics Corp For: Aug 03 Filed by: Gold Kelly

Wed, 05 Aug 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260805/26875789.html

Form 4 Camp4 Therapeutics Corp For: Aug 03 Filed by: Mandel-Brehm Josh

Wed, 05 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260805/26875773.html

Camp4 Therapeutics closes second tranche of $100M private placement

Tue, 04 Aug 2026 07:00:27 -0400

Camp4 Therapeutics Corporation (Nasdaq: CAMP) announced the closing of the second tranche of a previously announced private placement, raising approximately $50.1 million in gross proceeds.

The second closing involved the issuance of 10,756,498 shares of common stock priced at $1.53 per share, 39,306 shares priced at $1.65 to certain directors, employees, and consultants, and 21,925,368 pre-funded warrants at $1.5299 each. The securities purchase agreement was originally dated September 9, 2025.

The company said it intends to use the net proceeds to advance CMP-002, its lead investigational antisense oligonucleotide therapeutic candidate targeting SYNGAP1-related disorder. Camp4 recently received clearance from Australia's Therapeutic Goods Administration

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

Tue, 04 Aug 2026 07:00:00 -0400

Proceeds of $50.1 million will be used to support the Company’s advancement of CMP-002 for the treatment of SYNGAP1-related disorder

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the closing of the second tranche of its previously announced private placement pursuant to a securities purchase agreement, dated September 9, 2025, with certain institutional

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

Tue, 04 Aug 2026 07:00:00 -0400

Proceeds of $50.1 million will be used to support the Company’s advancement of CMP-002 for the treatment of SYNGAP1-related disorder

Camp4 Therapeutics gets Australian clearance for SYNGAP1 drug trial

Mon, 27 Jul 2026 07:02:41 -0400

Camp4 Therapeutics Corporation (Nasdaq: CAMP) said it received clearance from Australia's Therapeutic Goods Administration (TGA) and a local Human Research Ethics Committee (HREC) to initiate a Phase 1/2 clinical trial of CMP-002, an investigational antisense oligonucleotide (ASO) therapy targeting SYNGAP1-related disorder.

SYNGAP1-related disorder is a rare genetic condition affecting more than 10,000 individuals in the United States. It is characterized by intellectual disability in all patients, epilepsy in approximately 85%, and severe behavioral problems in approximately 70%. No approved disease-modifying therapies currently exist for the condition.

CMP-002 is designed to bind to a SYNGAP1-specific regulatory RNA to increase gene expression and restore

Camp4 Therapeutics gets Australian clearance for SYNGAP1 drug trial

Mon, 27 Jul 2026 07:02:41 -0400

CMP-002 is designed to bind to a SYNGAP1-specific regulatory RNA to increase gene expression and restore

CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder

Mon, 27 Jul 2026 07:00:00 -0400

Planned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorder

Regulatory milestone enables Company to raise up to $50 million through second closing of private placement announced September 2025

CAMBRIDGE, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that it has received clearance from

CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder

Mon, 27 Jul 2026 07:00:00 -0400

Planned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorder

Regulatory milestone enables Company to raise up to $50 million through second closing of private placement announced September 2025

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 17 Jul 2026 16:05:00 -0400

CAMBRIDGE, Mass., July 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on July 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase 8,000 shares of the Company’s common stock to a newly hired employee of the Company as an inducement material to such

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 17 Jul 2026 16:05:00 -0400

X4 Pharmaceuticals adds Kelly Gold to its board of directors

Wed, 01 Jul 2026 07:00:39 -0400

X4 Pharmaceuticals (Nasdaq: XFOR) announced the appointment of Kelly Gold to its board of directors, effective July 1, 2026. Gold will serve as an independent director and member of the Audit Committee, according to a press release from the company.

Gold currently serves as Chief Financial Officer at CAMP4 Therapeutics (Nasdaq: CAMP), where she oversees corporate finance and accounting, investor relations, and strategic financial planning. Before becoming CFO at CAMP4, she held roles in business development and finance at the same company.

Prior to CAMP4, Gold held corporate finance and business planning positions at Biogen, where she supported late-stage and marketed rare

StreetInsider.com News Articles

CAMP4 to Participate in Upcoming Investor Conferences

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

Form 4 Camp4 Therapeutics Corp For: Aug 03 Filed by: 5AM Ventures VII, L.P.

Form 4 Camp4 Therapeutics Corp For: Aug 03 Filed by: Schwab Andrew J.

Form 4 Camp4 Therapeutics Corp For: Aug 03 Filed by: Young Richard A

Form 4 Camp4 Therapeutics Corp For: Aug 03 Filed by: Maricich Yuri

Form 4 Camp4 Therapeutics Corp For: Aug 03 Filed by: Gold Kelly

Form 4 Camp4 Therapeutics Corp For: Aug 03 Filed by: Mandel-Brehm Josh

Camp4 Therapeutics closes second tranche of $100M private placement

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

Camp4 Therapeutics gets Australian clearance for SYNGAP1 drug trial

Camp4 Therapeutics gets Australian clearance for SYNGAP1 drug trial

CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder

CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals adds Kelly Gold to its board of directors